Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2025
Association between B-cell activating factor and future depressive symptoms in hemodialysis patients.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Dong-Young, Jang Woojin, Kim Beom, Lee Jae-Hon, Lee Young, Lee Yu Ho, Ahn Shin Young, Kim Jin Sug, Kim Yang Gyun, Hwang Hyeon Seok, Moon Ju-Young, Ryoo Jae-Hong, Teopiz Kayla M, Mansur Rodrigo B, Rosenblat Joshua D, McIntyre Roger S
Аннотация
OBJECTIVE: B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are cytokines that play critical roles in the maturation, homeostasis, and differentiation of B-cells. Both cytokines have also been associated with mental disorders. The link between inflammation and depression is well-established. Patients undergoing hemodialysis who also experience depressive symptoms exhibit a state of immune dysfunction. We hypothesized that BAFF and APRIL levels would influence future depressive symptoms in hemodialysis patients.
METHODS: We enrolled 72 hemodialysis patients without baseline depressive symptoms. Depressive symptoms were assessed annually for 2 years using the Beck Depression Inventory-II. The participants were measured for plasma BAFF, APRIL, and tumor necrosis factor-a levels. To evaluate the impact of these levels on the development of depressive symptoms, we performed Cox regression and Kaplan-Meier analysis.
RESULTS: Depressive symptoms were observed in 31 (43.1%) patients. In both univariate and multivariate Cox regression analyses, a 1 SD increase in BAFF was significantly associated with an increased risk of future depressive symptoms, with hazard ratios of 1.44 (95%CI 1.03-2.00) and 1.70 (95%CI 1.04-2.78), respectively. Higher BAFF groups had a significantly greater incidence of depressive symptoms over 2 years (p = 0.048).
CONCLUSION: Elevated plasma BAFF levels were significantly associated with the development of depressive symptoms in hemodialysis patients.
METHODS: We enrolled 72 hemodialysis patients without baseline depressive symptoms. Depressive symptoms were assessed annually for 2 years using the Beck Depression Inventory-II. The participants were measured for plasma BAFF, APRIL, and tumor necrosis factor-a levels. To evaluate the impact of these levels on the development of depressive symptoms, we performed Cox regression and Kaplan-Meier analysis.
RESULTS: Depressive symptoms were observed in 31 (43.1%) patients. In both univariate and multivariate Cox regression analyses, a 1 SD increase in BAFF was significantly associated with an increased risk of future depressive symptoms, with hazard ratios of 1.44 (95%CI 1.03-2.00) and 1.70 (95%CI 1.04-2.78), respectively. Higher BAFF groups had a significantly greater incidence of depressive symptoms over 2 years (p = 0.048).
CONCLUSION: Elevated plasma BAFF levels were significantly associated with the development of depressive symptoms in hemodialysis patients.